MergerLinks Daily Review
MergerLinks
Join a community of 250,000+ M&A professionals. Expand your network and discover new business opportunities.
Welcome to MergerLinks Daily Review.?Sign up here?to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.
Choice Hotels eyes $7.8bn Wyndham buy.
Top Abcam investor HBK voices support for $5.7bn sale.
You can access today’s complete newsletter?here.
Scroll down for more…
赛默飞世尔科技 , a supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services, agreed to acquire Olink Proteomics , a company dedicated to accelerating proteomics together with the scientific community,?from Summa Equity , a private equity firm, for $3.1bn.?
“The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine. Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms. Our company is uniquely positioned to bring this technology to customers enabling them to meaningfully accelerate discovery and scientific breakthroughs. We look forward to welcoming Olink’s colleagues to Thermo Fisher,” Marc N. Casper, Thermo Fisher Chairman, President and CEO.
Thermo Fisher is advised by Cravath, Swaine & Moore LLP and Vinge . Olink is advised by 高盛 , J.P. 摩根 , 瑞银集团 and 贝克?麦坚时 .?Summa Equity is advised by Ropes & Gray LLP (led by Suni Sreepada).
L Catterton , a private equity firm that invests in all major consumer segments, completed the acquisition of Thorne HealthTech , a science-driven wellness company, for $680m.
"As consumer investors, we closely follow enduring secular trends, including the consumer's increasing prioritization of health and wellness. As we begin this partnership with Thorne, returning this leading clinical brand to the private market, we look forward to focusing our resources and strategic planning on executing on Thorne's vision of delivering clinically backed outcomes utilizing specialized health tests and personalized supplement and wellness programs to patients around the globe," Marc Magliacano , L Catterton Co-Managing Partner of the Flagship Fund.
领英推荐
L Catterton was advised by 美国银行 and Kirkland & Ellis (led by Joshua Kogan, Marshall P. Shaffer and Daniel Yip). Thorne HealthTech was advised by CG Sawaya Partners (led by Irina Adler, Fuad Sawaya and David Istock)?and Wilson Sonsini Goodrich & Rosati (led by Rich Mullen, Philip Oettinger, Dana Hall and Ryan Greecher). Mitsui was advised by Debevoise & Plimpton (led by Ezra Borut and Morgan Hayes).
Wendel , an investment firm, agreed to acquire a 51% stake in IK Partners , a private equity firm, for €383m ($404m).?
"We are very proud to embark on this new entrepreneurial stage in Wendel's development with a high-quality company like IK, sharing the same values and investment philosophy. Wendel and IK are strongly committed to creating value in their portfolio companies, with a strong focus on establishing solid governance and supporting their operational and external growth. We look forward to working with the IK teams to ensure the success of this value-creating partnership. I am convinced that, in the years to come, we will find new opportunities for external growth and direct investments that will create value for Wendel's shareholders." Laurent Mignon, Wendel Group CEO.
IK Partners is advised by H/Advisors Maitland . Wendel is advised by?Rothschild & Co, Kekst CNC (led by?Todd Fogarty) and Primatice Conseil (led by?Olivier Labesse?and?Hugues Schmitt).
Choice Hotels eyes $7.8bn Wyndham buy.
Choice Hotels International proposed to acquire Wyndham Hotels & Resorts for about $7.8bn in a cash and stock deal that would create a US budget hotel giant, Reuters reported.
Demand for affordable hotels such as Choice and Wyndham are on the rise as persistent high inflation and recession sap consumer spending on travel. Shares of Wyndham rose about 22% before the bell.
Top Abcam investor HBK voices support for $5.7bn sale. (FS)
HBK Capital Management has become Abcam 's biggest shareholder and said it plans to vote in favor of the planned $5.7bn sale of the life sciences firm to Danaher,?Bloomberg?reported.
The US hedge fund has amassed a 7.5% stake in Abcam, according to a regulatory filing. That surpasses the roughly 6.2% holding owned by company founder Jonathan Milner, who’s been trying to persuade investors to reject the Danaher Corporation bid.
Interested to find more??Sign up here?to get full round up of your daily dose of blue-chip M&A news directly to your inbox.
You can access today’s complete newsletter?here.